Image_1_Endothelial Cells Promote Docetaxel Resistance of Prostate Cancer Cells by Inducing ERG Expression and Activating Akt/mTOR Signaling Pathway.tif by Wenhao Zhou (2855447)

“…<p>Docetaxel is a first-line chemotherapy for the treatment of patients with castration-resistant prostate cancer (CRPC). …”

Image_3_Endothelial Cells Promote Docetaxel Resistance of Prostate Cancer Cells by Inducing ERG Expression and Activating Akt/mTOR Signaling Pathway.tif by Wenhao Zhou (2855447)

“…<p>Docetaxel is a first-line chemotherapy for the treatment of patients with castration-resistant prostate cancer (CRPC). …”

Image_2_Endothelial Cells Promote Docetaxel Resistance of Prostate Cancer Cells by Inducing ERG Expression and Activating Akt/mTOR Signaling Pathway.tif by Wenhao Zhou (2855447)

“…<p>Docetaxel is a first-line chemotherapy for the treatment of patients with castration-resistant prostate cancer (CRPC). …”

CDK4/6 inhibition presents as a therapeutic option for pediatric and adult germ cell tumors and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms by Margaretha Skowron (3449309)

“…Although high cure rates at early stages can be achieved, metastases, resistance to cisplatin-based therapy, and late toxicities still represent a lethal threat, arguing for the need of new therapeutic options. …”

DataSheet_1_A Long Noncoding RNA, GAS5 Can Be a Biomarker for Docetaxel Response in Castration Resistant Prostate Cancer.docx by Yuting Shan (10841241)

Image_1_Promoter Methylation of the MGRN1 Gene Predicts Prognosis and Response to Chemotherapy of High-Grade Serous Ovarian Cancer Patients.tif by Xiao-fei Li (11041062)

DataSheet_1_DNA N6-Methyladenine (6mA) Modification Regulates Drug Resistance in Triple Negative Breast Cancer.pdf by Xianneng Sheng (10076839)

DataSheet_6_Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.pd... by Jeroen H. A. Creemers (9561569)

“…These findings were not more pronounced in patients with an alkaline phosphatase response during therapy.</p>Conclusion<p>Immune cell subsets in patients with mCRPC changed during radium-223 therapy, which warrants further research into the possible immunological consequences of these changes.…”

DataSheet_7_Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.pd... by Jeroen H. A. Creemers (9561569)

“…These findings were not more pronounced in patients with an alkaline phosphatase response during therapy.</p>Conclusion<p>Immune cell subsets in patients with mCRPC changed during radium-223 therapy, which warrants further research into the possible immunological consequences of these changes.…”

DataSheet_2_Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.pd... by Jeroen H. A. Creemers (9561569)

“…These findings were not more pronounced in patients with an alkaline phosphatase response during therapy.</p>Conclusion<p>Immune cell subsets in patients with mCRPC changed during radium-223 therapy, which warrants further research into the possible immunological consequences of these changes.…”

DataSheet_9_Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.do... by Jeroen H. A. Creemers (9561569)

“…These findings were not more pronounced in patients with an alkaline phosphatase response during therapy.</p>Conclusion<p>Immune cell subsets in patients with mCRPC changed during radium-223 therapy, which warrants further research into the possible immunological consequences of these changes.…”

DataSheet_5_Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.pd... by Jeroen H. A. Creemers (9561569)

“…These findings were not more pronounced in patients with an alkaline phosphatase response during therapy.</p>Conclusion<p>Immune cell subsets in patients with mCRPC changed during radium-223 therapy, which warrants further research into the possible immunological consequences of these changes.…”

DataSheet_1_Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.pd... by Jeroen H. A. Creemers (9561569)

“…These findings were not more pronounced in patients with an alkaline phosphatase response during therapy.</p>Conclusion<p>Immune cell subsets in patients with mCRPC changed during radium-223 therapy, which warrants further research into the possible immunological consequences of these changes.…”

DataSheet_8_Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.pd... by Jeroen H. A. Creemers (9561569)

“…These findings were not more pronounced in patients with an alkaline phosphatase response during therapy.</p>Conclusion<p>Immune cell subsets in patients with mCRPC changed during radium-223 therapy, which warrants further research into the possible immunological consequences of these changes.…”

DataSheet_4_Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.pd... by Jeroen H. A. Creemers (9561569)

“…These findings were not more pronounced in patients with an alkaline phosphatase response during therapy.</p>Conclusion<p>Immune cell subsets in patients with mCRPC changed during radium-223 therapy, which warrants further research into the possible immunological consequences of these changes.…”

DataSheet_3_Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.pd... by Jeroen H. A. Creemers (9561569)

“…These findings were not more pronounced in patients with an alkaline phosphatase response during therapy.</p>Conclusion<p>Immune cell subsets in patients with mCRPC changed during radium-223 therapy, which warrants further research into the possible immunological consequences of these changes.…”

Table_1_Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib.docx by Anja Charlotte Lundgren Mortensen (7403255)

“…In the present study, we have investigated whether therapy with the novel HSP90 inhibitor onalespib can potentiate the efficacy of cisplatin and potentially reverse cisplatin resistance in ovarian and head and neck cancer cells.…”

Image_1_Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib.TIFF by Anja Charlotte Lundgren Mortensen (7403255)

“…In the present study, we have investigated whether therapy with the novel HSP90 inhibitor onalespib can potentiate the efficacy of cisplatin and potentially reverse cisplatin resistance in ovarian and head and neck cancer cells.…”

Image_2_Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib.TIFF by Anja Charlotte Lundgren Mortensen (7403255)

“…In the present study, we have investigated whether therapy with the novel HSP90 inhibitor onalespib can potentiate the efficacy of cisplatin and potentially reverse cisplatin resistance in ovarian and head and neck cancer cells.…”

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... by Claire M. Douglas (21238238)

Subjects: